Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study
Arthritis & Rheumatology · 2025
DOI: 10.1002/art.43165 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Achille Marino und 31 weiteren Autor:innen. Beteiligte Einrichtung: ASST Gaetano Pini-CTO, Milan, Italy. Hauptthemen laut MEDLINE: Adalimumab, Uveitis, Antirheumatic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk.
Methods
We conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis. Cox proportional hazards regression was used to analyze risk factors for NIU recurrence.
Results
The study cohort comprised 114 patients (65 girls; 57%). Most commonly, patients presented with juvenile idiopathic arthritis–associated uveitis (JIA‐U) (52 of 114; 46%) or idiopathic uveitis (46 of 114; 40%). At ADA tapering, 46% of patients (53 of 114) experienced NIU recurrence after an overall median time of 30 weeks (interquartile range [IQR] 15–58 weeks) from the start of ADA tapering. Patients without recurrences were observed for a median of 70 weeks (IQR 48–98 weeks). Multivariate Cox regression analysis showed that a slower ADA tapering schedule was associated with a lower recurrence rate during the waning (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.21–0.74; P < 0.01). Subgroup analysis of patients with JIA‐U indicated that beginning ADA tapering after at least two years of disease inactivity significantly reduced recurrence risk (HR 0.65, 95% CI 0.43–0.95; P = 0.05). Among 59 patients (52%) who discontinued ADA, recurrence rates were similar between fast‐ and slow‐tapering groups (21% vs 33%; P = 0.6), but median time to recurrence was shorter with fast tapering (10 weeks vs 37 weeks; P = 0.05).
Conclusion
This study highlights the significant clinical impact of ADA tapering on uveitis recurrence risk, recommending a gradual, slow‐tapering approach with close monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ASST Gaetano Pini-CTO, Milan, Italy.
- Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, and Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
- Northwestern University, Chicago, Illinois.
- Watany Eye Hospital, Cairo, Egypt, and Research Institute of Ophthalmology, Giza, Egypt.
- Watany Eye Hospital, Cairo, Egypt.
ORCID-Profile: Cecilia B Chighizola
Zitieren
APA
Marino, A., Cicinelli, M. V., Miserocchi, E., Costi, S., Baldo, F., Gattinara, M. V., Scandale, P., Smith, S. D., Goldstein, D. A., Baddar, D., Gerges, T. K. A., Janetos, T. M., Ruiz-Cruz, M., Maruyama, K., Serafino, M., Camicione, P., Gupta, V., Amer, R., Dodds, E. M., …, & Pichi, F. (2025). Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.43165
Vancouver
Marino A, Cicinelli MV, Miserocchi E, Costi S, Baldo F, Gattinara MV, et al. Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study. Arthritis & Rheumatology. 2025. doi:10.1002/art.43165
BibTeX
@article{Marino2025,
author = {Marino, Achille and Cicinelli, Maria Vittoria and Miserocchi, Elisabetta and Costi, Stefania and Baldo, Francesco and Gattinara, Maurizio Virgilio and Scandale, Pierluigi and Smith, Scott D and Goldstein, Debra A and Baddar, Dina and Gerges, Terese K A and Janetos, Timothy M and Ruiz-Cruz, Matilde and Maruyama, Kazuichi and Serafino, Massimiliano and Camicione, Paola and Gupta, Vishali and Amer, Radgonde and Dodds, Emilio M and Inchauspe, Sebastian and Munk, Marion R and Carreño, Ester and Chee, Soon-Phaik and Agarwal, Aniruddha and Schlaen, Ariel and Gómez, Ramiro A and Couto, Cristobal A and Khairallah, Moncef and Neri, Piergiorgio and Chighizola, Cecilia B and Caporali, Roberto F and Pichi, Francesco},
title = {Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study},
journal = {Arthritis & Rheumatology},
year = {2025},
doi = {10.1002/art.43165}
}
EUVIMED